MedTrace Logo

Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program

NCT02933346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 907

Last updated 2023-05-24

No results posted yet for this study

Summary

Our study sought to examine nivolumab efficacy and safety in advanced NSCLC patients treated under the Temporary Authorization for Use (ATU, compassionate use) setting and describe their long-term clinical characteristics, notably the treatments they received after nivolumab discontinuation. The profile of these patients shows greater conformity to that of a non-selected population, yet the clinical data collection does not reflect "real life" conditions and stops when treatment ends, which does not enable us to get an overview of post-immunotherapy treatments.

Conditions

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Olivier MOLINIER, MD · CH Le Mans, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-01-31
Completion
2020-12-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933346 on ClinicalTrials.gov